Open CFD account Free Demo
Call: +248 4 671 903 Mail: [email protected]
Log In Open Account
Log In Open Account
Log In Open Account
News & Analysis
Open Account
News & Analysis
Open Account

BioNTech tops Q3 expectations – the stock is up

8 November 2022 By Klavs Valters

Share

BioNTech SE (NASDAQ:BNTX) reported its third quarter financial results on Monday.

The German pharmaceutical company beat both revenue and earnings per share (EPS) estimates for the quarter, sending the stock price higher.

The company reported revenue of $3.392 billion vs. $2.024 billion expected.

EPS reported at $6.841 per share vs. $3.352 per share estimate.

”Thanks to our strong execution in the third quarter of 2022, we updated our COVID-19 vaccine revenue guidance for the year 2022 to the upper end of the original range. We started shipments of our Omicron-adapted bivalent vaccines early in September and we expect to carry on with our deliveries throughout the fourth quarter of 2022,” Jens Holstein, CFO of BioNTech commented on the latest results.

”We believe in the potential of our COVID-19 franchise and plan to build on our leading position with ongoing innovations in this field. The power of our scientific innovation combined with our strong financial position allows us to accelerate and expand our diversified clinical pipeline and to create future growth in the interest of all stakeholders,” Holstein concluded.

 

The stock was up by around 2% during the session on Monday following the latest results, trading at $155.52 a share.

Stock performance

  • 1 month: +16.38%
  • 3 months: -7.00%
  • Year-to-date: -38.93%
  • 1 year: -35.10%

BioNTech price targets

  • JPMorgan: $132
  • Deutsche Bank: $250
  • HC Wainwright & Co.: $272
  • SVB Leerink: $224
  • Morgan Stanley: $194
  • Goldman Sachs: $206

BioNTech SE is the 411th largest company in the world with a market cap of $38.46 billion.

You can trade BioNTech SE (NASDAQ:BNTX) and many other stocks from the NYSE, NASDAQ, HKEX, ASX, LSE and DE with GO Markets as a Share CFD.

Sources: BioNTech SE, TradingView, Benzinga, CompaniesMarketCap

The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs. These documents are available here.

#Indice #Indices #IndicesTrading #IndexTrading #Shares #Stockmarket #Stocks